Cannabis for Inflammatory Bowel Disease

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

L'enllaç es desa al porta-retalls

Estat

Patrocinadors

Meir Medical Center

ASSAIG CLÍNIC: NCT01040910

BioSeek: nct01040910

Paraules clau

Resum

Background: The marijuana plant Cannabis has been used for centuries in the medicinal treatment of many disorders and is still the subject of medical research and public debate. Cannabinoids have been purported to alleviate a variety of neurological conditions such as MS-related symptoms including spasticity, pain, tremor and bladder dysfunction. Other neurological conditions like chronic intractable pain, dystonic movement disorders and Tourette's Syndrome were all reported to be alleviated by cannabis use. Cannabis has been used to treat anorexia in AIDS and cancer patients. In gastroenterology cannabis has been used to treat symptoms and diseases including anorexia, emesis, abdominal pain, gastroenteritis, diarrhoea, intestinal inflammation and diabetic gastroparesis.

Cannabinoids have also a profound anti inflammatory effect, mainly through the CB2 receptor. Cell mediated immunity may be impaired in chronic marijuana users. And a potent anti-inflammatory effect of cannabis was observed in rats . Studying the functional roles of the endocannabinoid system in immune modulation reveals that there are no major immune events which do not involve the endocannabinoid system. Cannabinoids shift the balance of pro-inflammatory cytokines and anti-inflammatory cytokines towards the T-helper cell type 2 profiles (Th2 phenotype), and suppress cell-mediated immunity whereas humoral immunity may be enhanced. They are therefore used for various inflammatory conditions including rheumatoid arthritis and asthma. In a mouse model of colitis cannabinoids were found to ameliorate inflammation and there are many anecdotal reports about the effect of cannabis in inflammatory bowel disease. However, there are no methodical reports of the effect of cannabis on inflammatory bowel disease. The aim of the proposed study is to examine in a double blind placebo controlled fashion the effect of smoking cannabis on disease activity in patients with IBD.

Dates

Darrera verificació:	11/30/2011
Primer enviat:	12/28/2009
Inscripció estimada enviada:	12/28/2009
Publicat per primera vegada:	12/29/2009
Última actualització enviada:	12/14/2011
Publicació de l'última actualització:	12/15/2011
Data d'inici de l'estudi real:	12/31/2009
Data estimada de finalització primària:	05/31/2012
Data estimada de finalització de l’estudi:	06/30/2012

Condició o malaltia

Crohn's Disease

Ulcerative Colitis

Intervenció / tractament

Drug: cannabis smoking for IBD

Drug: patients smoking non active cannabis

Fase

Fase 1/Fase 2

Grups de braços

Braç	Intervenció / tractament
Active Comparator: cannabis smoking for IBD patients with active disease receiving active cannabis for smoking	Drug: cannabis smoking for IBD smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
Placebo Comparator: patients smoking non active cannabis patients with active disease receiving cannabis from which active ingredients have been chemically removed	Drug: patients smoking non active cannabis smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed

Criteris d'elegibilitat

Edats elegibles per estudiar	20 Years Per a 20 Years
Sexes elegibles per estudiar	All
Accepta voluntaris saludables	Sí
Criteris	Inclusion Criteria: 1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study. 2. Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo. 3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC. 4. Age above 20. Exclusion Criteria: 1. Patients with a known mental disorder 2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug. 3. Pregnant women 4. Patients who are sensitive to any of the ingredients of the study medication. 5. Patients who are unable to give informed consent. 6. Patients who may need surgery in the near future.

Resultat

Mesures de resultats primaris

1. reduction of CDAI by 70 points [8 weeks]

Mesures de resultats secundaris

1. adverse events due to cannabis smoking [8 weeks]

2. change in quality of life before and at the end of study [8 weeks]

3. change in IL-10. IL-2. TGF beta [week 0 and week 8]

Cannabis for Inflammatory Bowel Disease

Paraules clau

anorèxia

cannabinoid

càncer

dolor abdominal

vòmit

inflamació

asma

gastroparèsia

colitis

gastroenteritis

artritis

tremolor

cànnabis

antiinflamatori